AIM Immunotech Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on a Special Meeting of Stockholders held by AIM Immunotech Inc. on April 30, 2025. The company is incorporated in Delaware and its common stock trades on the NYSE American under the symbol AIM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and stockholder voting results.
Material Changes and Voting Results
At the meeting, there were 72,290,030 outstanding shares entitled to vote, with a quorum present. Stockholders voted on Proposal 1 to approve amendments to the Certificate of Incorporation to effect a reverse stock split at a ratio of up to 1-for-100, with the specific ratio to be determined by the Board of Directors.
- For: 23,041,332 votes
- Against: 19,942,903 votes
- Abstain: 225,957 votes
The proposal was approved by the stockholders.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, or contingencies beyond the execution of the reverse stock split authorization.
Key Facts for Investor Verification
- Stockholders approved a reverse stock split authorization with a maximum ratio of 1-for-100.
- The Board of Directors retains sole discretion to determine the final split ratio and timing.
- The vote was close, with approximately 53.7% of votes cast in favor of the proposal.
- No financial performance data or liquidity metrics were disclosed in this specific filing.